Cytisine vs nicotine replacement therapy
It is very uncertain whether cytisine changes SAEs compared with nicotine replacement therapy (very low certainty).
- RR 1.15 [0.76, 1.75]1 study · 1310 participantsVery low
It is very uncertain whether cytisine changes SAEs compared with nicotine replacement therapy (very low certainty).
Varenicline may leads to lower SAEs compared with nicotine replacement therapy monotherapy (low certainty).
Varenicline showed no clear difference in SAEs compared with combination nicotine replacement therapy (low certainty).
The review found no eligible studies for this question.
Varenicline showed no clear difference in cardiac SAEs compared with combination nicotine replacement therapy (low certainty).
Cytisine showed no clear difference in SAEs compared with varenicline (low certainty).
Varenicline showed no clear difference in SAEs compared with bupropion (low certainty).
The review found no eligible studies for this question.
Varenicline showed no clear difference in neuropsychiatric SAEs compared with combination nicotine replacement therapy (low certainty).
It is very uncertain whether longer changes overall SAEs ‐ 26 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
The review found no eligible studies for this question.
Varenicline showed no clear difference in cardiac SAEs compared with bupropion (low certainty).
The review found no eligible studies for this question.
Varenicline showed no clear difference in neuropsychiatric SAEs compared with bupropion (low certainty).